Gastric cancer patient with MET amplification treated with crizotinib achieves long-term survival: a case report
This report describes a GC <i>MET</i> amplification patient who treated with crizotinib for 34 months. During the period, the patient's <i>MET</i> amplification mutation disappeared and gained high-quality life. After drug resistance developed, trametinib was used according to the new mutation sites. Until now. The patient got a good quality of life for three years, which is relatively rare among the reported cases.
Authors
- Saiqi Wang
- Huifang Lv
- Hui Wang (ORCID: https://orcid.org/0000-0003-2161-0150)
- Beibei Chen (ORCID: https://orcid.org/0000-0002-3720-001X)
- Weifeng Xu (ORCID: https://orcid.org/0000-0001-6682-3075)
- Yunduan He
- Jianzheng Wang (ORCID: https://orcid.org/0000-0002-2292-3629)
- Haiyan Kang (ORCID: https://orcid.org/0000-0002-4348-3810)
- Xiaobing Chen
- Jing Zhao
- Caiyun Nie
- Zhongkang Li (ORCID: https://orcid.org/0000-0003-1562-2438)
Institutions
- Zhengzhou University (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- AME Case Reports
- Published
- 2024-12-11
- DOI
- https://doi.org/10.21037/acr-24-118
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37